666P Final Results of Phase I/II Study of NUC-7738 As Monotherapy and in Combination with Pembrolizumab: Anti-tumor Immune Response in PD-1 Inhibitor-Resistant Patients

S. Blagden,M. Elshani,S.N. Symeonides, A. Skolariki, N.R. Haris, Z.Y. Boh, A. Dickson, I.H. Um, Y. Zhang, F.G. McKissock, E. Oelmann,J. Bloss,N. Cook,T.R.J. Evans,R. Plummer,D.J. Harrison

Annals of Oncology（2024）

Cited 0|Views9

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined